Project Grant R01AI189500
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maryland, Baltimore a Project Grant totaling $427,625 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on April 6, 2026, with a completion date of March 31, 2028. This research grant funds a comprehensive study titled "Modeling the Vaginal Microbiome: Predicting BV Recurrence and Identifying Preventative Targets," which addresses bacterial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective February 1, 2026, through January 31, 2028. This investigator-initiated research project delivers scientific investigation into Candida glabrata populations during gastrointestinal tract colonization and intra-abdominal candidiasis (IAC), with particular...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Michigan a $411,078 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. The award supports research to identify novel antifungal compounds derived from symbiotic bacteria—microorganisms that co-exist with and provide benefits to eukaryotic hosts—with the objective of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $1,193,457 to the University of Massachusetts Medical School on July 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop fungal antigen resources for vaccines and diagnostics. This collaborative project, executed through a consortium involving UMass Chan, the University of Texas at San Antonio (UTSA), and the University of Wisconsin-Milwaukee...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $197,240 through the Allergy and Infectious Diseases Research program (CFDA 93.855) under a Project Grant mechanism, with performance occurring from September 3, 2025 through August 31, 2027. This mentored career development award supports research investigating the mechanisms by which fungal extracellular vesicles activate innate immune pathways, specifically...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of California, Davis a $441,204 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on preventing invasive candidiasis caused by Candida albicans. The award, issued February 13, 2026, with a completion date of January 31, 2028, funds biomedical research aimed at understanding and preventing systemic fungal infections in...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Pittsburgh a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on unrecognized azole resistance among Candida parapsilosis causing bloodstream infections. The award, effective February 1, 2026 through January 31, 2028, supports investigator-initiated biomedical research addressing infectious disease mechanisms and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Colorado-Denver $412,422 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year Project Grant beginning February 1, 2026, and concluding January 31, 2028. This award funds investigator-initiated biomedical research to investigate the role of immunoglobulin A (IgA) antibodies in regulating Candida glabrata colonization within the intestinal...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $899,850 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Whitehead Institute for Biomedical Research, effective February 20, 2026, through January 31, 2031. This award supports fundamental research aimed at elucidating the molecular mechanisms by which apicomplexan parasites recognize and invade host cells—a critical process for parasite survival...
- Federal Grant Award Summary The University of Vermont & State Agricultural College received a $449,393 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 20, 2026, with completion targeted for January 31, 2028. This research initiative investigates the differential invasive capacity of Providencia alcalifaciens, an understudied enterobacterium linked to foodborne...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Maine a $777,795 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective April 1, 2026, through March 31, 2031. This research initiative focuses on investigating virulence mechanisms underlying vulvovaginal candidiasis (VVC), a fungal infection affecting approximately 50% of women at least twice during their lifetimes. The project will deliver scientific research aimed at understanding how specific Candida albicans strains drive vaginal epithelial cell exfoliation through dysregulation of epithelial signaling pathways, particularly Type I interferon (IFN-I) and integrin signaling, thereby advancing knowledge of disease pathogenesis beyond current paradigms that attribute VVC primarily to environmental factors. The research will produce multiple scientific deliverables through two integrated research aims: identification of pathways colonizing strains utilize to activate IFN-I signaling and assessment of differential IFN-I activation between VVC and colonizing strains (Aim 1); and determination of differential integrin signaling in exfoliation processes and evaluation of Candida-bacterial co-infection synergy (Aim 2). The research will utilize in vitro assays with human vaginal epithelial cells to generate findings applicable to human disease mechanisms, ultimately informing future therapeutic approaches to VVC management and prevention.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $777.8k | 4/1/26 |